Total (N = 50) | ||
---|---|---|
Age, y | Median (Min, max) | 52.5 (27, 68) |
Sex | Male, n (%) | 23 (46.0%) |
ECOG, n (%) | 0 | 3 (6.0%) |
1 | 47 (94.0%) | |
Tumor types | CRC | 13 (26.0%) |
NSCLC | 8 (16.0%) | |
GC/GEJC | 3 (6.0%) | |
Endometrial cancer | 3 (6.0%) | |
Breast cancer | 2 (4.0%) | |
Others | 21 (42.0%) | |
Prior antitumor Regimen, n (%) | 0 | 0 |
1 | 5 (10.0%) | |
2 | 7 (14.0%) | |
≥ 3 | 37 (74.0%) | |
Prior anti-PD-1 therapy | Yes | 24 (48.0%) |
No | 26 (52.0%) |